Bloomberg Law
Drug, Device Manufacturers to Face Hill Scrutiny in 2019
January 8, 2019
Combating high drug and device prices is a bipartisan goal in Congress, and House Democrats in control of key oversight committees have made clear their plans to pursue investigations putting pharma CEOs under scrutiny. Manufacturers need to prep now to explain policies and prepare for public relations issues.
Capabilities
Suggested News & Insights
Ninth Circuit Rejects $8.5M Award Of Attorneys’ Fees to FCA WhistleblowerApril 14, 2026Sidley Represents AIP in Its US$1.272 Billion Acquisition of Avanos MedicalApril 14, 2026DOJ Announces First FCA Settlement Resolving Title VII Discrimination AllegationsApril 13, 2026Sidley Represents Telix Pharmaceutical in US$2.1 Billion Partnering Agreement With RegeneronApril 13, 2026White House and DOJ Announce Sweeping New Anti-Fraud InitiativesApril 10, 2026The End of PPM 1.0: And the Emergence of a More Durable Model for InvestorsMarch 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory